Linked Life Data

15942884

Source:http://linkedlifedata.com/resource/pubmed/id/15942884

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2005-6-8
pubmed:abstractText
The significant impact of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is now recognized. This recognition has led to increased efforts to provide evidence-based, appropriate treatment of AECOPD, to minimize its negative impact. This article reviews the bacterial etiology of AECOPD and clinical trials (both placebo-controlled and antibiotic comparison trials) that support the use of antibiotics for AECOPD, with an emphasis on the role of newer fluoroquinolones for the treatment of patients with this condition. A discussion of patient stratification that permits identification of those who require initial aggressive antibiotic therapy is presented.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1537-6591
pubmed:author
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
41 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S177-85
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Moxifloxacin for the treatment of acute exacerbations of chronic obstructive pulmonary disease.
pubmed:affiliation
Division of Pulmonary, Critical Care and Sleep Medicine, State University of New York, and Department of Veterans Affairs, Western New York Healthcare System, Buffalo, New York, USA. ssethi@buffalo.edu
pubmed:publicationType
Journal Article, Comparative Study, Review, Research Support, Non-U.S. Gov't